Follicular lymphoma - Symptoms, Causes, Treatment & Prevention

```html

Overview

Follicular lymphoma (FL) is a slow‑growing (indolent) type of non‑Hodgkin lymphoma that originates from B‑lymphocytes (a kind of white blood cell) in the lymph nodes, spleen, bone marrow, and sometimes the gastrointestinal tract. It accounts for about 20%–25% of all non‑Hodgkin lymphomas in the United States and Europe, making it the second most common NHL subtype after diffuse large B‑cell lymphoma.<sup>[1] Mayo Clinic</sup>

FL most often affects adults between the ages of **50 – 70 years**. Men and women are diagnosed at similar rates, although a slight male predominance has been noted in some population studies.<sup>[2] SEER Cancer Statistics</sup>

Because it progresses slowly, many patients are diagnosed incidentally during routine blood work or imaging for an unrelated problem. While FL is considered incurable with current therapies, most patients live many years—often 10 – 15 years or more—with a good quality of life when disease is well managed.

Symptoms

Symptoms vary widely because FL can involve many parts of the lymphatic system. Some patients have no symptoms at all. When symptoms do appear, they typically develop gradually.

General / Systemic Symptoms

• Unexplained weight loss (≥10 % of body weight over 6 months).
• Fever (often low‑grade, “night sweats” are common).
• Fatigue or a feeling of constant tiredness not relieved by rest.
• Night sweats that soak clothing or bedding.

Lymph Node–Related Symptoms

• Painless swelling of one or more lymph nodes—commonly in the neck, armpits, or groin.
• Enlarged spleen (splenomegaly) causing a feeling of fullness in the left upper abdomen.
• Enlarged liver (hepatomegaly)—often detected on exam or imaging.

Bone Marrow / Blood‑Related Symptoms

• Anemia → shortness of breath, paleness.
• Thrombocytopenia → easy bruising or bleeding.
• Leukopenia → increased susceptibility to infections.

Gastrointestinal & Other Organ Involvement

• Abdominal pain or swelling if the disease involves the gut or mesenteric lymph nodes.
• Rarely, skin lesions or lung nodules when FL spreads outside typical lymphoid sites.

Because many of these signs overlap with other conditions, a thorough medical evaluation is essential for an accurate diagnosis.

Causes and Risk Factors

The exact cause of follicular lymphoma is unknown, but several genetic and environmental factors increase risk.

Genetic Mutations

• BCL2 gene translocation (t(14;18)(q32;q21)) – the hallmark genetic abnormality in >80 % of FL cases, leading to over‑expression of the BCL2 protein that prevents cell death.<sup>[3] WHO Classification of Tumours</sup>
• Additional mutations in genes such as EZH2, CREBBP, and TNFRSF14 are commonly found and may influence disease behavior.

Environmental & Lifestyle Factors

• History of **autoimmune diseases** (e.g., rheumatoid arthritis, Sjögren’s syndrome) modestly raises risk.<sup>[4] CDC</sup>
• Exposure to **pesticides, herbicides, or industrial solvents** has been linked with a slight increase in NHL risk, though data specific to FL are limited.
• **Chronic immune stimulation**—for example, longstanding infections such as hepatitis C—may contribute.

Demographic Risk Factors

• Age > 50 years (median diagnosis age ≈ 60).
• Male gender (≈ 55 % of cases).
• White ethnicity shows a higher incidence in the United States, though FL occurs worldwide.

Family History

First‑degree relatives of someone with a non‑Hodgkin lymphoma have a 2‑3 fold increased risk, suggesting a hereditary component, but the absolute risk remains low.

Diagnosis

Diagnosing follicular lymphoma involves a combination of clinical evaluation, imaging, laboratory studies, and, most critically, a tissue biopsy.

Initial Evaluation

• Detailed medical history and physical exam focusing on lymph node regions, spleen, and liver.
• Complete blood count (CBC) with differential to assess anemia, thrombocytopenia, or leukopenia.
• Serum chemistry panel (LDH, β‑2 microglobulin) – elevated levels often correlate with tumor burden.

Imaging Studies

• Computed Tomography (CT) scans of the neck, chest, abdomen, and pelvis to map nodal involvement.
• Positron Emission Tomography (PET)/CT – useful for staging and assessing response to therapy; FL typically shows modest FDG uptake.
• Ultrasound of the neck or abdomen when palpable lymphadenopathy is present.

Biopsy & Pathology

1. Excisional lymph node biopsy (preferred) – whole node removed allows evaluation of architecture.
2. Core needle biopsy – may be used when excision is not feasible, but can miss follicular pattern.
3. Pathology confirms:
   • Follicular growth pattern (grades 1‑3 based on proportion of centroblasts).
   • Immunophenotype: CD20+, CD10+, BCL2+, BCL6+.
   • Presence of t(14;18) by FISH or PCR.

Staging

FL is staged using the Ann & Bodle system (same as other NHLs):

• Stage I – involvement of a single lymph node region (or a single extralymphatic organ).
• Stage II – two or more lymph node regions on the same side of the diaphragm.
• Stage III – lymph node regions on both sides of the diaphragm.
• Stage IV – diffuse or disseminated involvement of one or more extralymphatic organs (e.g., bone marrow).

“Low‑grade/early stage” disease (often Stage I–II) may be observed without immediate therapy, whereas advanced disease usually requires treatment.

Treatment Options

Treatment is individualized based on stage, tumor grade, patient age, comorbidities, and personal preferences. The goals are to control disease, preserve quality of life, and prolong survival.

Watchful Waiting (Active Surveillance)

• Appropriate for asymptomatic, low‑tumor‑burden patients (often Stage I‑II, grade 1‑2).
• Patients are monitored with physical exams and imaging every 3–6 months.<sup>[5] NCCN Guidelines</sup>

Immunotherapy

• Rituximab (anti‑CD20 monoclonal antibody) – the backbone of most FL regimens; can be given alone or with chemotherapy.
• Other anti‑CD20 agents (obinutuzumab, ofatumumab) are options for rituximab‑refractory disease.

Chemo‑Immunotherapy

Common regimens (often given for 6‑8 cycles):

• R‑CHOP – rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
• R‑CVP – rituximab, cyclophosphamide, vincristine, prednisone (less anthracycline toxicity).
• Bendamustine + Rituximab (BR) – effective, especially in older adults.

Targeted Therapies

• Idelalisib (PI3Kδ inhibitor) – for relapsed/refractory FL after at least two prior therapies.
• Lenalidomide (immunomodulatory drug) – often combined with rituximab (R‑lenalidomide) in the “R‑2” regimen.
• EZH2 inhibitors (tazemetostat) – approved for EZH2‑mutated or follicular lymphoma with no satisfactory alternative.

Stem Cell Transplant

High‑dose chemotherapy followed by autologous (patient’s own) stem‑cell rescue may be considered for younger patients with multiple relapses.

Radiation Therapy

• Low‑dose involved‑field radiotherapy (24 Gy) can eradicate localized disease (Stage I) and is sometimes used as sole therapy.
• May also be used for palliation of symptomatic bulky nodes.

Supportive & Lifestyle Measures

• Vaccinations (influenza, pneumococcal, COVID‑19) – important because therapies can weaken immunity.
• Management of cytopenias with growth factors (e.g., G‑CSF) or transfusions when needed.
• Exercise, balanced nutrition, and psychosocial support improve overall well‑being.

Living with Follicular Lymphoma

Even though FL is chronic, many patients lead active, fulfilling lives. Below are practical tips for day‑to‑day management.

Regular Follow‑Up

• Visit your hematologist/oncologist every 3–6 months (more often if on active treatment).
• Blood work (CBC, LDH, metabolic panel) and imaging as recommended.

Symptom Monitoring

• Keep a diary of new or worsening symptoms (fevers, weight loss, night sweats).
• Report any rapid lymph node enlargement, unexplained bruising, or infection signs promptly.

Nutrition & Exercise

• Aim for a Mediterranean‑style diet rich in fruits, vegetables, whole grains, lean protein, and healthy fats.
• Moderate aerobic activity (150 min/week) improves fatigue and cardiovascular health.
• Strength training 2 times/week helps maintain muscle mass, especially during chemotherapy.

Managing Treatment Side Effects

• Infusion reactions – pre‑medicate with acetaminophen and antihistamine; stay hydrated.
• Neuropathy (from vincristine) – dose adjustments, vitamin B complex, and physiotherapy.
• Hair loss – consider head scarves or wigs; usually temporary.
• Infection risk – practice good hand hygiene, avoid sick contacts, and consider prophylactic antibiotics if neutropenic.

Emotional & Social Support

• Join patient advocacy groups such as the Lymphoma Research Foundation or CancerCare.
• Consider counseling or mindfulness‑based stress reduction to cope with anxiety.
• Open communication with family and workplace about needed accommodations.

Financial & Practical Resources

• Check eligibility for drug assistance programs (e.g., Roche’s patient support for rituximab).
• Explore insurance benefits for infusion centers and transportation assistance.

Prevention

Because the precise cause of follicular lymphoma is unclear, no guaranteed preventive measures exist. However, adopting general cancer‑risk‑reduction strategies may lower overall likelihood:

• Maintain a healthy weight and engage in regular physical activity.
• Limit exposure to known occupational chemicals (pesticides, solvents) by using protective equipment.
• Avoid tobacco use and limit excessive alcohol consumption.
• Stay up‑to‑date with recommended vaccinations to reduce infections that can chronically stimulate the immune system.
• Promptly treat chronic autoimmune conditions under specialist care.

Complications

If follicular lymphoma is left untreated or becomes refractory, several serious complications can arise:

• Transformation to aggressive lymphoma (usually diffuse large B‑cell lymphoma) – occurs in 2‑3 % per year; associated with rapid growth, high LDH, and worse prognosis.<sup>[6] WHO</sup>
• Bone‑marrow failure – leading to severe anemia, infections, or bleeding.
• Secondary malignancies – risk of therapy‑related myelodysplastic syndromes or acute leukemia, especially after alkylating agents.
• Infections – both disease‑related immune dysfunction and treatment‑induced immunosuppression increase susceptibility.
• Organ compression – large lymph nodes can press on the airway, blood vessels, or gastrointestinal tract, causing pain or obstruction.

When to Seek Emergency Care

---

Sources:
[1] Mayo Clinic. “Follicular lymphoma.” Mayo Clinic, 2024.
[2] SEER Program, National Cancer Institute. “Non‑Hodgkin Lymphoma Statistics.” 2023.
[3] WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 5th ed., 2022.
[4] Centers for Disease Control and Prevention. “Non‑Hodgkin Lymphoma and Autoimmune Disease.” 2023.
[5] National Comprehensive Cancer Network (NCCN) Guidelines for B‑cell Lymphomas, Version 2.2024.
[6] Swerdlow SH et al. “Transformation of Follicular Lymphoma.” Blood, 2022;140(14):1509‑1518.

```